S. Narayanan

发表

Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia

M. Power, R. Broady, D. Hogge, 2017, Leukemia & lymphoma.

Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity‐score Adjusted Analysis

M. Power, R. Broady, D. Hogge, 2018, Clinical lymphoma, myeloma & leukemia.

High Induction Response Rate, but Poor Long-Term Disease Free Survival in Elderly Patients Treated Aggressively for Acute Lymphoblastic Leukemia

A. Tantiworawit, M. Power, R. Broady, 2014 .

Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.

Hatem M. Alahwal, F. Kuchenbauer, M. Power, 2021, Clinical lymphoma, myeloma & leukemia.

Donor KIR Genotype Does Not Affect VZV Reactivation after Allogeneic Haematopoietic Stem Cell Transplantation.

C. Craddock, P. Moss, S. Nagra, 2005 .

Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma

R. Gascoyne, J. Connors, R. Brinkman, 2008 .

Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort.

F. Kuchenbauer, J. Brandwein, M. Power, 2020, Clinical lymphoma, myeloma & leukemia.

Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort

A. Karsan, F. Kuchenbauer, M. Power, 2022, European journal of haematology.

Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.

Matthew P Wright, M. Power, D. Hogge, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predictors of Clinical Response in Patients with High Risk Acute Myeloid Leukemia Receiving Treatment with the Histone Deacetylase Inhibitor Sodium Valproate.

C. Bradbury, C. Bunce, C. Craddock, 2005 .

CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies

Scott D. Brown, Victoria J. Hodgson, H. Atkins, 2022, Frontiers in Immunology.

Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation

C. Craddock, A. Ho, P. Mahendra, 2005, Bone Marrow Transplantation.

Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

M. Power, R. Broady, D. Hogge, 2012 .

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

J. Connors, M. Power, R. Broady, 2011, Leukemia & lymphoma.

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohort

J. Connors, M. Power, R. Broady, 2012, British journal of haematology.

Excellent real‐world outcomes of adults with Burkitt lymphoma treated with CODOX‐M/IVAC plus or minus rituximab

L. Sehn, J. Connors, G. Slack, 2018, British journal of haematology.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

R. Gascoyne, L. Sehn, J. Connors, 2015, Clinical lymphoma, myeloma & leukemia.

Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.

M. Power, R. Broady, D. Hogge, 2019, Clinical lymphoma, myeloma & leukemia.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

M. Power, R. Broady, D. Hogge, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

R. Gascoyne, L. Sehn, J. Connors, 2013 .

Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.

M. Power, R. Broady, D. Hogge, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

A. Tantiworawit, M. Power, R. Broady, 2012, Leukemia & lymphoma.

Aurin Tricarboxylic Acid Protects against Red Blood Cell Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinemia

P. Mcgeer, E. Mcgeer, Moonhee Lee, 2014, PloS one.

Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

F. Kuchenbauer, M. Power, S. Nantel, 2021, Blood.

High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

J. Yeung, M. Power, D. Hogge, 2009 .

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

J. Connors, M. Power, R. Broady, 2011, Leukemia & lymphoma.